Vagus Nerve Stimulators (VNS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Vagus Nerve Stimulators (VNS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Vagus Nerve Stimulators (VNS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Vagus Nerve Stimulators (VNS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A Vagus Nerve Stimulator is a device comprised of an electrical pacemaker that sends electrical stimulation through surgically implanted electrodes to target the vagus nerve. VNSs are utilized to treat neurological disorders such as epilepsy and depression.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Vagus Nerve Stimulators (VNS) under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Vagus Nerve Stimulators (VNS) and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Vagus Nerve Stimulators (VNS) under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
Introduction
Vagus Nerve Stimulators (VNS) Overview
Products under Development
Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development
Table Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development
Table Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development
Vagus Nerve Stimulators (VNS) - Pipeline Products by Segment
Table Vagus Nerve Stimulators (VNS) - Pipeline Products by Segment
Table Vagus Nerve Stimulators (VNS) - Pipeline Products by Segment
Vagus Nerve Stimulators (VNS) - Pipeline Products by Territory
Table Vagus Nerve Stimulators (VNS) - Pipeline Products by Territory
Table Vagus Nerve Stimulators (VNS) - Pipeline Products by Territory
Vagus Nerve Stimulators (VNS) - Pipeline Products by Regulatory Path
Table Vivistim Paired VNS System - Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord Injury: A Pilot Randomized Control Trial.
Table Vivistim Paired VNS System - Vagal Nerve Stimulation in Enhanced Stroke Recovery: The VALOR Registry
Table Vivistim Paired VNS System - Vagus Nerve Stimulation (VNS) During Rehabilitation Using the Vivistim System: Post-Market Study for Stroke Rehabilitation in a Home Environment for Subjects With Chronic Stroke (VNS-REHAB At-Home)
Table Vivistim Paired VNS System - Vivistim Registry for Paired VNS Therapy (GRASP)
Table Setpoint Medical Corp - Ongoing Clinical Trials Overview
Table Implantable Bioelectronic Device - Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Synergia Medical SA Company Overview
Synergia Medical SA Pipeline Products & Ongoing Clinical Trials Overview
Table Synergia Medical SA Pipeline Products & Ongoing Clinical Trials Overview
Jul 10, 2024: Setpoint Medical Announces Positive Topline Results from Landmark Reset-Ra Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
Jul 10, 2024: SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
Jun 06, 2024: LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
Mar 21, 2024: SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
Mar 19, 2024: Tampa General Conducts First Procedure on the West Coast of Florida With Device Designed to Revive Arm Function After Stroke
Mar 13, 2024: SetPoint wins second FDA breakthrough device nod for neurostim device
Mar 13, 2024: SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
Mar 04, 2024: LivaNova to Present at the Barclays Global Healthcare Conference
Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
Feb 23, 2024: Breakthrough Stroke Treatment at Penn State Health Offers Patients New Hope
Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
Dec 26, 2023: electroCore Expands Intellectual Property Portfolio
Nov 15, 2023: Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
Oct 24, 2023: TIME Picks MicroTransponder's Vivistim Paired VNS System for 2023 Best Inventions List in Medical Care Category
Oct 17, 2023: electroCore Announces Two-Year Extension of gammaCore Device Listing in the NHS Supply Chain Catalogue
Oct 11, 2023: electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
Oct 03, 2023: SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis
Sep 14, 2023: ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device